Claims for Patent: 4,696,949

Summary for Patent: 4,696,949

Title:	Novel tri-phenyl alkane and alkene derivatives and their preparation and use
Abstract:	The invention provides novel compounds of the formula: ##STR1## wherein n is 0 to 4, R.sub.1 and R.sub.2, which can be the same or different are H, OH, alkoxy of 1 to 4 carbon atoms, benzyloxy or methoxymethoxy; R.sub.3 is H, OH, halogen, alkoxy of 1 to 4 carbon atoms, benzyloxy, methoxymethoxy, 2,3-dihydroxypropoxy or ##STR2## wherein m is 1 or 2, R.sub.6 and R.sub.7, which can be the same or different are H or an alkyl group of 1 to 4 carbon atoms, or ##STR3## can form an N-containing three-, four-, five- or six-membered heterocyclic ring; R.sub.4 is OH, F, Cl, Br, I, mesyloxy, tosyloxy, alkylcarbonyloxy of 1 to 4 C-atoms, formyloxy or CH.sub.2 R.sub.4 is replaced by CHO; R.sub.5 is H or OH; or R.sub.4 and R.sub.5 together form an --O-- bridge between the carbon atoms to which they are attached, and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof. Processes for the preparation of these compounds are described, and also novel pharmaceutical compositions containing them. These compounds exhibit valuable pharmacological properties as estrogenic, anti-estrogenic, and progestanic agents. They are also effective against oestrogen-dependent tumors. Certain compounds are useful as chemical intermediates for the preparation of pharmacologically active compounds of the invention.
Inventor(s):	Toivola; Reijo J. (Oulu, FI), Karjalainen; Arto J. (Oulu, FI), Kurkela; Kauko O. A. (Oulu, FI), Soderwall; Marja-Liisa (Oulu, FI), Kangas; Lauri V. M. (Turki, FI), Blanco; Guillermo L. (Oulu, FI), Sunduiqst; Hannu K. (Kaarina, FI)
Assignee:	Farmos Group Ltd. (Turku, FI)
Application Number:	06/823,856
Patent Claims:	1. A compound of the formula: ##STR50## or a non-toxic pharmaceutically acceptable salt or N-oxides thereof. 2. A compound according to claim 1 which is 4-chloro-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene or a non-toxic pharmaceutically acceptable salt thereof. 3. A compound according to claim 1 which is the trans-isomer of 4-chloro-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene or a non-toxic pharmaceutically acceptable salt thereof. 4. A compound according to claim 1 which is the citrate of the trans-isomer of 4-chloro-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene. 5. A pharmaceutical composition suitable for treating hormone-dependent tumours comprising an anti-tumour effective amount of a compound of claim 1 or a non-toxic pharmaceutically acceptable salt thereof and a compatible pharmaceutically carrier therefor. 6. A method of producing an anti-oestrogenic effect in a subject in which such an effect is desired which comprises administering to said subject an anti-oestrogenic effective amount of a compound as defined in claim 3 or a non-toxic pharmaceutically acceptable salt thereof. 7. A method according to claim 6 in which an antioestrogenic effect is produced in a subject suffering from an oestrogen-dependent tumour.